RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai FosunPharma is one of the companies bidding to acquire a 70% stake in India’s SymbiotecPharma, which supplies steroid-hormone APIs to global markets. Actis, a PE fund, paid $55 million for the 70% block of stock in 2013, and it is now offering its shares for about $350 million, a $500 million valuation for Symbiotec. Symbiotec has revenues of about $60 million per year. Fosun is currently closing its $1.1 billion purchase of a 74% stake in India’s Gland Pharma, a generic drugmaker.
Source: China Bio Today
